https://www.reuters.com/business/healthcare-pharmaceuticals/mesoblast-soars-us-fdas-nod-review-lead-drug-candidate-2023-03-08/#:~:text=The%20brokerage%20said%20it%20expects,%241.140%20earlier%20in%20the%20session.
Brokerage Jefferies said it expects "significant" U.S. sales of the drug (nah, therapy) in fiscal 2024.
PS: I will be adding on any pull backs.
This post is not to be construed as investment advice because it is not meant to be.
https://www.reuters.com/business/healthcare-pharmaceuticals/mesob...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
-0.040(3.54%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.12 | $1.14 | $1.09 | $10.61M | 9.616M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 241716 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.10 |
Change
-0.040 ( 3.00 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.14 | $1.09 | 1809171 | ||
| Last updated 15.59pm 09/05/2024 ? | |||||
| MSB (ASX) Chart |